CN100374456C - 用于选择性癌症治疗的特异性人抗体 - Google Patents

用于选择性癌症治疗的特异性人抗体 Download PDF

Info

Publication number
CN100374456C
CN100374456C CNB018228852A CN01822885A CN100374456C CN 100374456 C CN100374456 C CN 100374456C CN B018228852 A CNB018228852 A CN B018228852A CN 01822885 A CN01822885 A CN 01822885A CN 100374456 C CN100374456 C CN 100374456C
Authority
CN
China
Prior art keywords
cell
ser
scfv
gly
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018228852A
Other languages
English (en)
Chinese (zh)
Other versions
CN1551886A (zh
Inventor
Y·哈盖
J·拉扎罗维茨
R·盖伊
O·利普施茨
E·桑顿
A·莱瓦农
D·普拉克辛
T·佩雷茨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of CN1551886A publication Critical patent/CN1551886A/zh
Application granted granted Critical
Publication of CN100374456C publication Critical patent/CN100374456C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CNB018228852A 2000-12-29 2001-12-31 用于选择性癌症治疗的特异性人抗体 Expired - Fee Related CN100374456C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75118100A 2000-12-29 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
CN1551886A CN1551886A (zh) 2004-12-01
CN100374456C true CN100374456C (zh) 2008-03-12

Family

ID=25020844

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018228852A Expired - Fee Related CN100374456C (zh) 2000-12-29 2001-12-31 用于选择性癌症治疗的特异性人抗体

Country Status (15)

Country Link
EP (1) EP1353937A4 (enExample)
JP (1) JP2004524023A (enExample)
KR (1) KR20030091952A (enExample)
CN (1) CN100374456C (enExample)
AU (1) AU2002246737B2 (enExample)
BR (1) BR0116763A (enExample)
CA (1) CA2433227A1 (enExample)
CZ (1) CZ20031983A3 (enExample)
HU (1) HUP0400775A2 (enExample)
IL (1) IL156690A0 (enExample)
MX (1) MXPA03005944A (enExample)
NZ (1) NZ527173A (enExample)
PL (1) PL365758A1 (enExample)
RU (1) RU2316564C2 (enExample)
WO (1) WO2002059264A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
KR20060107501A (ko) * 2003-06-30 2006-10-13 바이오-테크널러지 제너럴 (이스라엘) 리미티드 특이적인 인간 항체
EP1877444A2 (en) 2005-04-26 2008-01-16 Pfizer, Inc. P-cadherin antibodies
WO2010078916A1 (en) * 2008-12-19 2010-07-15 Philogen S.P.A. Immunocytokines for tumour therapy with chemotherapeutic agents
BR112013000452A2 (pt) * 2010-07-09 2020-02-11 Affibody Ab Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto
CN101948534B (zh) * 2010-08-19 2014-05-28 中国科学院生物物理研究所 一种筛选抗体的方法
GB201310544D0 (en) * 2013-06-13 2013-07-31 Ucb Pharma Sa Obtaining an improved therapeutic ligand
PL3590962T3 (pl) * 2014-10-23 2022-01-31 Singh Molecular Medicine, Llc Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
SG11201704726VA (en) * 2014-12-17 2017-07-28 Intrexon Corp Intercalated single-chain variable fragments
GB201506868D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
US12509530B2 (en) 2015-08-27 2025-12-30 Singh Moelcular Medicine, LLC Single domain antibodies directed against intracellular antigens
CA2998270A1 (en) * 2015-10-01 2017-04-06 Ospedale San Raffaele S.R.L. Tcr and uses thereof
HUE054131T2 (hu) 2015-11-19 2021-08-30 Revitope Ltd Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben
CR20220578A (es) * 2016-09-14 2023-01-17 Teneobio Inc Anticuerpos de unión a cd3
EP3559035A1 (en) 2016-12-21 2019-10-30 TeneoBio, Inc. Anti-bcma heavy chain-only antibodies
MY200973A (en) * 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
TW202010757A (zh) 2018-04-11 2020-03-16 美商英伊布里克斯公司 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
US12590169B2 (en) 2018-10-11 2026-03-31 Inhibrx Biosciences, Inc. 5T4 single domain antibodies and therapeutic compositions thereof
EP3969621A4 (en) 2019-05-14 2023-01-25 Prometheus Biosciences, Inc. TL1A PATIENT SELECTION METHODS, SYSTEMS AND DEVICES
IL302791A (en) * 2020-11-13 2023-07-01 Prometheus Biosciences Inc Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a
GB202019817D0 (en) * 2020-12-15 2021-01-27 Univ Oxford Innovation Ltd Ligand-binding polypeptides and uses thereof
CN116333100A (zh) * 2022-10-31 2023-06-27 南京欧凯生物科技有限公司 一种重组人的lgM抗体快速纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1251532A (zh) * 1997-01-22 2000-04-26 德克萨斯州立大学董事会 凝血和肿瘤治疗的组织因子方法和组合物
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140470A (en) * 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
CN1251532A (zh) * 1997-01-22 2000-04-26 德克萨斯州立大学董事会 凝血和肿瘤治疗的组织因子方法和组合物
US6132730A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment

Also Published As

Publication number Publication date
CN1551886A (zh) 2004-12-01
WO2002059264A2 (en) 2002-08-01
JP2004524023A (ja) 2004-08-12
AU2002246737B2 (en) 2007-03-01
EP1353937A2 (en) 2003-10-22
CZ20031983A3 (cs) 2005-07-13
WO2002059264A3 (en) 2003-03-06
KR20030091952A (ko) 2003-12-03
PL365758A1 (en) 2005-01-10
IL156690A0 (en) 2004-01-04
NZ527173A (en) 2006-03-31
BR0116763A (pt) 2004-03-09
CA2433227A1 (en) 2002-08-01
EP1353937A4 (en) 2005-04-13
RU2003123100A (ru) 2005-03-10
MXPA03005944A (es) 2005-04-29
HUP0400775A2 (en) 2007-05-02
RU2316564C2 (ru) 2008-02-10

Similar Documents

Publication Publication Date Title
AU2002246737B2 (en) Specific human antibodies for selective cancer therapy
AU2002246737A1 (en) Specific human antibodies for selective cancer therapy
US20040002450A1 (en) Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001822A1 (en) Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
CN101671393A (zh) 血管生成素-2的特异结合剂
KR20040044408A (ko) 항 ｔｒａｉｌ-ｒ 항체
US7132510B2 (en) Specific human antibodies for selective cancer therapy
CN101479296A (zh) Trail受体结合剂和其用途
EP1117691A1 (en) Methods for producing human tumor antigen specific antibodies
KR102698752B1 (ko) 암 치료법에서 괴사를 표적화하기 위한 인간화 항-핵 항체
JP2005503756A (ja) 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用
JP2005503756A5 (enExample)
CA2491363A1 (en) Antibodies and uses thereof
CN101300021A (zh) 抗体及其用途
EP1033406A1 (en) Inducer for production of antigen-specific antibody, expression vector containing gene therefor, and method of inducing production of antigen-specific antibody
KR20050059001A (ko) 치료적 처리를 위한 조성물 및 방법
CN110734494B (zh) 抗tspan8单克隆抗体及其用途
US20040208877A1 (en) Antibodies and uses thereof
JP2012515158A (ja) 癌の予防・治療剤
Nadal Isolation and validation of novel monoclonal antibodies targeting the tumor microenvironment for the selective delivery of cytokines payloads
EP3998280A1 (en) Hybridoma and method for producing same, and monoclonal antibody and method for producing same
KR20060003882A (ko) 하이브리도마 부재하의 폴리클로날 및 모노클로날 항체의생체외 제조 및 불멸화된 세포 집단의 생성 방법
CN117843793A (zh) 抗间皮素抗体、抗原结合片段及其用途
AU2002246738A1 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee